Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0045 USD
Change Today +0.0015 / 50.00%
Volume 20.0K
As of 1:49 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

xeno transplants corp (XENO) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/17/15 - $0.0080
52 Week Low
12/19/14 - $0.0010
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XENO TRANSPLANTS CORP (XENO)

Related News

No related news articles were found.

xeno transplants corp (XENO) Related Businessweek News

No Related Businessweek News Found

xeno transplants corp (XENO) Details

Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.

xeno transplants corp (XENO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

xeno transplants corp (XENO) Key Developments

Xeno Transplants Corporation Files Form 15

Xeno Transplants Corporation has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XENO:US $0.00 USD +0.0015

XENO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XENO.
View Industry Companies

Industry Analysis


Industry Average

Valuation XENO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENO TRANSPLANTS CORP, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at